Loading...

Nabriva Therapeutics plc

NBRV•NASDAQ
Healthcare
Biotechnology
$1.42
$0.01(0.71%)

Nabriva Therapeutics plc (NBRV) Stock Overview

Explore Nabriva Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.3/100

Key Financials

Market Cap4.5M
P/E Ratio-0.07
EPS (TTM)$-19.67
ROE-2.02%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.31

NBRV Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nabriva Therapeutics plc (NBRV) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.31.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.07 and a market capitalization of 4.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NBRVStats details for NBRV are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NBRVAnalyst Recommendations details for NBRV are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

CEO

Dr. Colin Broom M.D.

Employees

39

Headquarters

25-28 North Wall Quay, Dublin

Founded

2017

Frequently Asked Questions

;